Coming Soon


  • A Phase IIb Randomized, Double-blind, Parallel Placebo- and Active-controlled Study to Assess the Efficacy and Safety of Vamorolone in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD)

    Brief Description: The study is a Phase IIb randomized, double-blind, parallel group, placebo and active-controlled study to evaluate the efficacy, safety, and pharmacodynamics of vamorolone in boys with DMD. To learn more about the study eligibility and participating sites, please contact us at info@trinds.com.
    Sponsor: ReveraGen
  • A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys with Duchenne Muscular Dystrophy (DMD)

    Brief Description: This study is an extension of the Phase II Dose Finding study evaluating the exon skipping intervention, NS-065/NCNP-01, targeted for the skipping of exon 53. The study will evaluate the tolerability and the effect of low and high IV doses of NS-065/NCNP-01 after an additional 24-week of weekly infusions. Patients who completed the NS-065/NCCNP-01 trial are eligible to enroll. To learn more about the study eligibility and participating sites please contact us at info@trinds.com.
    Sponsor: NS Pharma